Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks

British Journal of Dermatology

Volumn 172, Issue 1, 2015, Pages 239-243

  Anforth, R ^a,b   Carlos, G ^a,b   Clements, A ^b,c   Kefford, R ^b,c,d   Fernandez Penas P ^a,b  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d MELANOMA INSTITUTE AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DABRAFENIB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; OXIME; PROTEIN KINASE INHIBITOR; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE; SULFONAMIDE;

ACNE; ACTINIC KERATOSIS; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CYST; DARIER DISEASE; FEMALE; FOLLICULITIS; HISTOLOGY; HUMAN; HYPERKERATOSIS; HYPERPIGMENTATION; KERATOSIS; MALE; MELANOCYTIC NEVUS; METASTATIC MELANOMA; PANNICULITIS; PHOTOSENSITIVITY; PLANTAR HYPERKERATOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SKIN CARCINOMA; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; TRANSIENT ACANTHOLYTIC DERMATOSIS; TREATMENT DURATION; VERRUCA VULGARIS; VERRUCAL KERATOSIS; VITILIGO; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DRUG ERUPTIONS; MELANOMA; METASTASIS; MIDDLE AGED; SKIN NEOPLASMS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ERUPTIONS; FEMALE; HUMANS; IMIDAZOLES; INDOLES; MALE; MAP KINASE KINASE KINASES; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; OXIMES; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; PYRIDONES; PYRIMIDINONES; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84920733853     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13200     Document Type: Article

References (26)

1. Flaherty KT, Infante JR, Daud A, et al,. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-703.
2. Flaherty KT, Puzanov I, Kim KB, et al,. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-19.
3. Hauschild A, Grob JJ, Demidov LV, et al,. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-65.
4. Hatzivassiliou G, Song K, Yen I, et al,. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464: 431-5.
5. Heidorn SJ, Milagre C, Whittaker S, et al,. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010; 140: 209-21.
6. Anforth R, Liu M, Nguyen B, et al,. Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib. Australas J Dermatol 2013; in press.
7. Anforth R, Fernandez-Penas P, Long GV,. Cutaneous toxicities of RAF inhibitors. Lancet Oncol 2013; 14: e11-18.
8. Anforth RM, Blumetti TC, Kefford RF, et al,. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol 2012; 167: 1153-60.
9. Chu EY, Wanat KA, Miller CJ, et al,. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol 2012; 67: 1265-72.
10. Mattei PL, Alora-Palli MB, Kraft S, et al,. Cutaneous effects of BRAF inhibitor therapy: a case series. Ann Oncol 2013; 24: 530-7.
11. Balch CM, Gershenwald JE, Soong SJ, et al,. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-206.
12. Hauschild A, Grob J-J, Demidov LV, et al,. An update on BREAK-3, a phase III, randomized trial: dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). J Clin Oncol 2013; 31 (15 Suppl.): abstr. 9013.
13. Hauschild A, McArthur G, Robert R, et al,. Vemurafenib improves overall survival compared with dacarbazine in advanced BRAFV600-mutated melanoma: updated results from a phase 3 randomized, multicenter trial. Pigment Cell Melanoma Res 2013; 26: 958.
14. Sosman JA, Daud A, Weber JS, et al,. BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM). J Clin Oncol 2013; 31 (15 Suppl.): abstr. 9005.
15. Chapman PB, Hauschild A, Robert C, et al,. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
16. Anforth R, Cristina T, Blumetti MP, et al,. Systemic retinoid therapy for chemoprevention of nonmelanoma skin cancer in a patient treated with vemurafenib. J Clin Oncol 2012; 30: e165-7.
17. Anforth R, Blumetti TC, Clements A, et al,. Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors. Br J Dermatol 2013; 169: 1310-13.
18. Anforth R, Tembe V, Blumetti T, Fernandez-Peñas P,. Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors. Pigment Cell Melanoma Res 2012; 25: 569-72.
19. Ganzenmueller T, Hage E, Yakushko Y, et al,. No human virus sequences detected by next generation sequencing in benign verrucous skin tumors occurring in BRAF-inhibitor-treated patients. Exp Dermatol 2013; 22: 725-9.
20. Cohen PR, Bedikian AY, Kim KB,. Appearance of new vemurafenib-associated melanocytic nevi on normal-appearing skin: case series and a review of changing or new pigmented lesions in patients with metastatic malignant melanoma after initiating treatment with vemurafenib. J Clin Aesthet Dermatol 2013; 6: 27-37.
21. Haenssle HA, Kraus SL, Brehmer F, et al,. Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: importance of sequential dermoscopy. Arch Dermatol 2012; 148: 1183-5.
22. Schmitt L, Schumann T, Inhoff O, et al,. Eruptive nevi mimicking wart-like lesions under selective BRAF inhibition in a 37-year-old female melanoma patient. Case Rep Dermatol 2013; 5: 69-72.
23. McClenahan P, Lin LL, Tan JM, et al,. BRAFV600E mutation status of involuting and stable nevi in dabrafenib therapy with or without trametinib. JAMA Dermatol 2014; 150: 1079-82.
24. Zimmer L, Hillen U, Livingstone E, et al,. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 2012; 30: 2375-83.
25. Dalle S, Poulalhon N, Debarbieux S, et al,. Tracking of second primary melanomas in vemurafenib-treated patients. JAMA Dermatol 2013; 149: 488-90.
26. Perier-Muzet M, Thomas L, Poulalhon N, et al,. Melanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopy. J Invest Dermatol 2014; 134: 1351-8.